Your session is about to expire
← Back to Search
Device
Registry Group for Patent Ductus Arteriosus
N/A
Waitlist Available
Led By Shyam Sathanandam, MD
Research Sponsored by Le Bonheur Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
The objective of this study is to demonstrate the continued safety and efficacy in a real-world setting of transcatheter device closure of the PDA in premature infants less than 2kg in weight at the time of device implant using the Amplatzer Piccolo Occluder device and other devices performed in the USA.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Device Embolization (Safety)
Pulmonary or Aortic Vessel Stenosis (Safety)
Rate of Effective PDA Closure (Effectiveness)
+2 moreSecondary outcome measures
Significant obstruction of the aorta
Significant obstruction of the left pulmonary artery
Trial Design
1Treatment groups
Experimental Treatment
Group I: Registry GroupExperimental Treatment1 Intervention
All participants will have the same data collected at the same time points.
Find a Location
Who is running the clinical trial?
AbbottIndustry Sponsor
752 Previous Clinical Trials
473,162 Total Patients Enrolled
Le Bonheur Children's HospitalLead Sponsor
27 Previous Clinical Trials
5,016,049 Total Patients Enrolled
Shyam Sathanandam, MDPrincipal InvestigatorNational Principal Investigator
Share this study with friends
Copy Link
Messenger